Hydrocortisone aceponate is a synthetic corticosteroid that is used topically to treat inflammatory skin conditions. It is a prodrug, meaning that it is inactive when applied to the skin but is converted to the active form, hydrocortisone, in the body. Hydrocortisone aceponate is highly potent and has a long duration of action. It is typically applied to the affected area once or twice daily. The exact mechanism of action of hydrocortisone aceponate is not fully understood, but it is thought to work by suppressing the immune system and reducing inflammation. Research on hydrocortisone aceponate has focused on its effectiveness in treating various skin conditions, including eczema, psoriasis, and dermatitis. The compound is also being investigated for its potential to treat other inflammatory conditions, such as asthma and arthritis. Studies have shown that hydrocortisone aceponate is generally safe and effective for topical use, but it can cause side effects such as skin thinning, acne, and stretch marks. '
hydrocortisone aceponate: RN given refers to (11beta)-isomers; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68921 |
| CHEMBL ID | 2106309 |
| CHEBI ID | 135746 |
| SCHEMBL ID | 3697 |
| MeSH ID | M0176269 |
| Synonym |
|---|
| hydrocortisone aceponate |
| efficort |
| 74050-20-7 |
| D06876 |
| efficort (tn) |
| hydrocortisone aceponate (inn) |
| CHEBI:135746 |
| [(8s,9s,10r,11s,13s,14s,17r)-17-(2-acetyloxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] propanoate |
| hydrocortisone 17-propionate 21-acetate |
| CHEMBL2106309 |
| cortavance |
| 11beta,17,21-trihydroxy pregn-4-ene-3,20-dione 21-acetate 17-propionate |
| unii-2340up1l2g |
| aceponate d'hydrocortisone [french] |
| aceponate d'hydrocortisone |
| aceponato de hidrocortisona [spanish] |
| hydrocortisoni aceponas [latin] |
| suniderma |
| hydrocortisone aceponate [inn] |
| 2340up1l2g , |
| hydrocortisoni aceponas |
| aceponato de hidrocortisona |
| hydrocortisone aceponate component of easotic |
| hydrocortisone aceponate [green book] |
| easotic component hydrocortisone aceponate |
| hydrocortisone aceponate [who-dd] |
| 11.beta.,17,21-trihydroxy pregn-4-ene-3,20-dione 21-acetate 17-propionate |
| hydrocortisone aceponate (ema epar: veterinary) |
| SCHEMBL3697 |
| AKOS027326791 |
| DB14538 |
| Q15409432 |
| (8s,9s,10r,11s,13s,14s,17r)-17-(2-acetoxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl propionate |
| NCGC00532512-01 |
| hydrocortisone 17-propionate 21-acetate 100 microg/ml in acetonitrile |
| F82273 |
| MS-28453 |
| hydrocortisoneaceponate |
| pregn-4-ene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)-, (11?)-; (11?)-21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)pregn-4-ene-3,20-dione; cortisol 17-propionate 21-acetate; hydrocortisone 17-propionate 21-acetate; hydrocortisone aceponate; re |
| CS-0066287 |
| HY-116691 |
| hydrocortisoni aceponas (latin) |
| 21-(acetyloxy)-11beta-hydroxy-17alpha-(propionyloxy)-4-pregnene-3,20-dione |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The evaluation of the benefit/risk ratio (BRR) for topical glucocorticoids (TGC) allows the comparison of active ingredients and thereby includes aspects of dosage (blanching response, BR) as well as adverse effects (skin atrophy)." | ( Hydrocortisone aceponate activity and benefit/risk ratio in relation to reference topical glucocorticoids. Beck, GM; Kreft, B; Neubert, RH; Sischka, U; Wohlrab, J, 2010) | 1.8 |
| Class | Description |
|---|---|
| corticosteroid hormone | Any of a class of steroid hormones that are produced in the adrenal cortex. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.65) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (54.55%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (13.64%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (31.82%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||